<DOC>
	<DOC>NCT02068768</DOC>
	<brief_summary>The purpose of this prospective clinical study is to examine the short-term safety and efficacy of the Avenue®- L interbody Spinal Fusion System with VerteBRIDGE® plating to treat one and two level degenerative disc disease between L2 and S1 with a focus on fusion rate.</brief_summary>
	<brief_title>Multicenter Study of the Avenue L Interbody Spinal Fusion System Using VerteBRIDGE Plating and Posterior Fixation</brief_title>
	<detailed_description />
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>Subjects must be candidates for onlabel use of the Avenue L device (have degenerative disc disease, use only at one or two contiguous levels, posterior fixation must be used, autograft must be used in the interbody cage) Subject must be skeletally mature at the time of surgery, i.e. the subject must be at least 21 years of age at the time of surgery Subject should have had a minimum of 6 months of nonoperative treatment prior to surgery The placement of the Avenue L device must be a primary surgery Subject must be willing to sign the consent form and be able to return for all follow up visits. Subject must not have had prior surgery at the operative level(s) Subject is known to have substance or alcohol addictions Subject has lateral curvature of the spine (scoliosis, all types) Subject is a prisoner Subject is pregnant Subject has an active infection or sepsis at the time of surgery Subject has any neuromuscular disorder that would preclude accurate neurologic evaluations</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>fusion</keyword>
	<keyword>lateral interbody fusion system</keyword>
	<keyword>lumbar spine</keyword>
	<keyword>degenerative disc disease</keyword>
</DOC>